Description
Non-Fucosylated Anti-Human VEGFR2 (121B) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Gastric cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced VEGFR2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
VEGFR2
Full Name
vascular endothelial growth factor receptor 2
Alternative Names
Kinase Insert Domain Receptor, Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase), Vascular Endothelial Growth Factor Receptor 2, Protein-Tyrosine Kinase Receptor Flk-1, Fetal Liver Kinase 1, EC 2.7.10.1, VEGFR2, FLK1, Tyrosine Kinase Growth Factor Receptor;
Gene ID
3791
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
121B
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Gastric cancer
